Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Issued (2017 - 2025)

Historic Shares Issued for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $3.1 million.

  • Crinetics Pharmaceuticals' Shares Issued fell 9359.36% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $539.0 million, marking a year-over-year increase of 1662.25%. This contributed to the annual value of $970.0 million for FY2024, which is 16287.21% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Shares Issued of $3.1 million as of Q3 2025, which was down 9359.36% from $2.9 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Shares Issued's 5-year high stood at $528.6 million during Q4 2024, with a 5-year trough of -$42000.0 in Q2 2021.
  • Moreover, its 5-year median value for Shares Issued was $3.1 million (2025), whereas its average is $76.3 million.
  • Data for Crinetics Pharmaceuticals' Shares Issued shows a peak YoY increase of 27504047.62% (in 2022) and a maximum YoY decrease of 10008.68% (in 2022) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Issued (Quarter) stood at $162.0 million in 2021, then crashed by 100.01% to -$13000.0 in 2022, then surged by 221269.23% to $28.8 million in 2023, then soared by 1738.31% to $528.6 million in 2024, then plummeted by 99.42% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $2.9 million for Q2 2025, and $4.4 million during Q1 2025.